AB
SLNO

Amalgamated Bank’s Soleno Therapeutics SLNO Stock Holding History

Amalgamated Bank’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,467
Closed -$68K – 2635
2025
Q4 		$68K Buy
1,467
+581
+66% +$31.9K ﹤0.01% 1763
2025
Q3 		$60K Hold
886
– – ﹤0.01% 1794
2025
Q2 		$74K Hold
886
– – ﹤0.01% 1755
2025
Q1 		$63K Buy
886
+125
+16% +$6.09K ﹤0.01% 1755
2024
Q4 		$34K Hold
761
– – ﹤0.01% 1943
2024
Q3 		$38K Hold
761
– – ﹤0.01% 1926
2024
Q2 		$31K Buy
+761
New +$32.2K ﹤0.01% 1981

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Amalgamated Bank's SLNO Position: Q1 2026 in Review

Amalgamated Bank sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 1,467 shares — an estimated $68K sold.

Amalgamated Bank first reported a position in SLNO in Q2 2024 and held it in 7 quarters. The position peaked at $74K in Q2 2025. 227 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Amalgamated Bank reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,467 Soleno Therapeutics shares in Q1 2026, an estimated $68K.
  • Amalgamated Bank first reported a position in Soleno Therapeutics in Q2 2024 and held it in 7 quarters.
  • Amalgamated Bank's Soleno Therapeutics position peaked at $74K in Q2 2025.
  • 227 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.